27571264|t|Flow-Induced Dispersion Analysis for Probing Anti-dsDNA Antibody Binding Heterogeneity in Systemic Lupus Erythematosus Patients: Toward a New Approach for Diagnosis and Patient Stratification
27571264|a|Detection of immune responses is important in the diagnosis of many diseases. For example, the detection of circulating autoantibodies against double-stranded DNA (dsDNA) is used in the diagnosis of Systemic Lupus Erythematosus (SLE). It is, however, difficult to reach satisfactory sensitivity, specificity, and accuracy with established assays. Also, existing methodologies for quantification of autoantibodies are challenging to transfer to a point-of-care setting. Here we present the use of flow-induced dispersion analysis (FIDA) for rapid (minutes) measurement of autoantibodies against dsDNA. The assay is based on Taylor dispersion analysis (TDA) and is fully automated with the use of standard capillary electrophoresis (CE) based equipment employing fluorescence detection. It is robust toward matrix effects as demonstrated by the direct analysis of samples composed of up to 85% plasma derived from human blood samples, and it allows for flexible exchange of the DNA sequences used to probe for the autoantibodies. Plasma samples from SLE positive patients were analyzed using the new FIDA methodology as well as by standard indirect immunofluorescence and solid-phase immunoassays. Interestingly, the patient antibodies bound DNA sequences with different affinities, suggesting pronounced heterogeneity among autoantibodies produced in SLE. The FIDA based methodology is a new approach for autoantibody detection and holds promise for being used for patient stratification and monitoring of disease activity.
27571264	0	32	Flow-Induced Dispersion Analysis	T059	C0022885
27571264	37	44	Probing	T059	C0022885
27571264	45	64	Anti-dsDNA Antibody	T116,T129	C2746079
27571264	65	72	Binding	T044	C1167622
27571264	73	86	Heterogeneity	T080	C0019409
27571264	90	118	Systemic Lupus Erythematosus	T047	C0024141
27571264	119	127	Patients	T101	C0030705
27571264	155	164	Diagnosis	T062	C1704656
27571264	169	176	Patient	T101	C0030705
27571264	177	191	Stratification	T062	C1514983
27571264	192	201	Detection	T061	C1511790
27571264	205	221	immune responses	T042	C0301872
27571264	242	251	diagnosis	T062	C1704656
27571264	260	268	diseases	T047	C0012634
27571264	287	296	detection	T061	C1511790
27571264	300	311	circulating	T169	C0175630
27571264	312	326	autoantibodies	T116,T129	C0004358
27571264	335	354	double-stranded DNA	T114,T123	C0311474
27571264	356	361	dsDNA	T114,T123	C0311474
27571264	378	387	diagnosis	T062	C1704656
27571264	391	419	Systemic Lupus Erythematosus	T047	C0024141
27571264	421	424	SLE	T047	C0024141
27571264	475	486	sensitivity	T081	C0036667
27571264	488	499	specificity	T081	C0037791
27571264	505	513	accuracy	T080	C0443131
27571264	531	537	assays	T059	C0005507
27571264	554	567	methodologies	T062	C0086912
27571264	572	586	quantification	T081	C1709793
27571264	590	604	autoantibodies	T116,T129	C0004358
27571264	688	720	flow-induced dispersion analysis	T059	C0022885
27571264	722	726	FIDA	T062	C0242481
27571264	732	737	rapid	T080	C0456962
27571264	739	746	minutes	T079	C0439232
27571264	748	777	measurement of autoantibodies	T059	C1272321
27571264	786	791	dsDNA	T114,T123	C0311474
27571264	797	802	assay	T059	C0005507
27571264	815	841	Taylor dispersion analysis	T059	C0022885
27571264	843	846	TDA	T062	C0242481
27571264	861	870	automated	T169	C0205554
27571264	887	895	standard	T080	C1442989
27571264	896	921	capillary electrophoresis	T059	C0201699
27571264	923	925	CE	T059	C0201699
27571264	933	942	equipment	T073	C0014672
27571264	953	965	fluorescence	T070	C0016315
27571264	966	975	detection	T061	C1511790
27571264	983	989	robust	T080	C2986815
27571264	1004	1011	effects	T080	C1280500
27571264	1035	1041	direct	T080	C1947931
27571264	1042	1061	analysis of samples	T059	C1303103
27571264	1084	1090	plasma	T031	C0032105
27571264	1104	1109	human	T016	C0086418
27571264	1110	1123	blood samples	T031	C0178913
27571264	1143	1160	flexible exchange	T201	C4019011
27571264	1168	1181	DNA sequences	T086	C0162326
27571264	1190	1195	probe	T114,T130	C0012893
27571264	1204	1218	autoantibodies	T116,T129	C0004358
27571264	1220	1234	Plasma samples	T031	C0444263
27571264	1240	1243	SLE	T047	C0024141
27571264	1244	1252	positive	T033	C1446409
27571264	1253	1261	patients	T101	C0030705
27571264	1267	1275	analyzed	T062	C0936012
27571264	1290	1294	FIDA	T062	C0242481
27571264	1295	1306	methodology	T062	C0086912
27571264	1321	1329	standard	T080	C1442989
27571264	1330	1338	indirect	T080	C0439852
27571264	1339	1357	immunofluorescence	T059	C0079603
27571264	1362	1386	solid-phase immunoassays	T059	C0005507
27571264	1407	1414	patient	T101	C0030705
27571264	1415	1425	antibodies	T116,T129	C0003241
27571264	1426	1431	bound	T044	C1167622
27571264	1432	1445	DNA sequences	T086	C0162326
27571264	1461	1471	affinities	T070	C1510827
27571264	1495	1508	heterogeneity	T080	C0019409
27571264	1515	1529	autoantibodies	T116,T129	C0004358
27571264	1542	1545	SLE	T047	C0024141
27571264	1551	1555	FIDA	T062	C0242481
27571264	1562	1573	methodology	T062	C0086912
27571264	1596	1608	autoantibody	T116,T129	C0004358
27571264	1609	1618	detection	T061	C1511790
27571264	1656	1663	patient	T101	C0030705
27571264	1664	1678	stratification	T062	C1514983
27571264	1683	1713	monitoring of disease activity	T058	C1283169